Glucopyranosyl lipid A-stable emulsion-activated toll-like receptor 4 (GLA-SE/TLR4)

Glucopyranosyl lipid A-stable emulsion (GLA-SE) is a vaccine adjuvant consisting of the synthetic TLR4 agonist glucopyranosyl lipid A formulated in an oil-in-water stable emulsion. The GLA component is a man-made hexaacylated analog of lipid A, with a defined disaccharide phosphate structure and six C14 acyl chains, designed to activate the toll-like receptor 4 (TLR4) pathway on antigen-presenting cells, leading to robust enhancement of both humoral and cellular immune responses[1][2][4][6]. GLA-SE strongly induces Th1 immunity and has demonstrated efficacy and safety in preclinical and clinical studies as an adjuvant for multiple vaccines—including against influenza, tuberculosis, Ebola, malaria, and cancer—by increasing antigen-specific antibody titers and promoting durable T-cell responses[4][5][6]. The stable emulsion formulation is engineered to further boost immunogenicity. GLA-SE is not the ultimate molecular target: it acts by stimulating TLR4, so the true therapeutic target is **toll-like receptor 4**, while "GLA-SE" itself is an engineered ligand and formulation, not a natural cellular entity. Thus, describing “Immune system stimulation via Glucopyranosyl Lipid A Adjuvant-Stable Emulsion” as a target is **incorrect**, as the biologically meaningful target is TLR4, not the adjuvant formulation itself[6][2][4].

Other names

GLA-SEGlucopyranosyl lipid adjuvant-stable emulsionSynthetic lipid A-stable emulsionGlucopyranosyl lipid A (GLA)GLATLR4 agonist GLA-SE

Agonism of toll-like receptor 4 (TLR4) on antigen-presenting cells Induction of Th1-skewed immune response Enhancement of humoral and cellular immune responses